Paysign, Inc. Announces Acquisition of Gamma Innovation’s Assets, Appoints Michael Ngo as Chief Innovation Officer
Paysign (NASDAQ: PAYS) has acquired the assets of Gamma Innovation , strengthening its position in plasma donor and pharmaceutical patient engagement technologies. The acquisition includes key assets such as a donor engagement app and a specialized CRM platform designed for the blood and plasma collection industry.
As part of this strategic move, Michael Ngo, former Managing Member of Gamma, has been appointed as Paysign's Chief Innovation Officer. The company also welcomes key team members including Howard Steidle, Bei Xu, and Sam Wang, bringing expertise in business strategy, AI-driven analytics, and software development.
The integration aims to enhance Paysign's engagement, compensation, and resource management solutions across core markets, particularly strengthening relationships with plasma clients and bolstering patient affordability solutions.
Paysign (NASDAQ: PAYS) ha acquisito gli asset di Gamma Innovation, rafforzando la sua posizione nelle tecnologie di coinvolgimento dei donatori di plasma e dei pazienti farmaceutici. L'acquisizione include asset chiave come un app per il coinvolgimento dei donatori e una piattaforma CRM specializzata progettata per l'industria della raccolta di sangue e plasma.
Come parte di questa mossa strategica, Michael Ngo, ex Managing Member di Gamma, è stato nominato Chief Innovation Officer di Paysign. L'azienda dà il benvenuto anche a membri chiave del team, tra cui Howard Steidle, Bei Xu e Sam Wang, portando competenze in strategia aziendale, analisi basate su AI e sviluppo software.
L'integrazione mira a migliorare le soluzioni di coinvolgimento, compensazione e gestione delle risorse di Paysign nei mercati principali, rafforzando in particolare le relazioni con i clienti di plasma e potenziando le soluzioni per l'affordabilità dei pazienti.
Paysign (NASDAQ: PAYS) ha adquirido los activos de Gamma Innovation, fortaleciendo su posición en las tecnologías de compromiso de donantes de plasma y pacientes farmacéuticos. La adquisición incluye activos clave como una aplicación de compromiso de donantes y una plataforma CRM especializada diseñada para la industria de recolección de sangre y plasma.
Como parte de este movimiento estratégico, Michael Ngo, ex miembro gerente de Gamma, ha sido nombrado Director de Innovación de Paysign. La empresa también da la bienvenida a miembros clave del equipo, incluidos Howard Steidle, Bei Xu y Sam Wang, que aportan experiencia en estrategia empresarial, análisis impulsados por IA y desarrollo de software.
La integración tiene como objetivo mejorar las soluciones de compromiso, compensación y gestión de recursos de Paysign en los mercados clave, fortaleciendo particularmente las relaciones con los clientes de plasma y mejorando las soluciones de asequibilidad para los pacientes.
Paysign (NASDAQ: PAYS)가 Gamma Innovation의 자산을 인수하여 플라스마 기증자 및 제약 환자 참여 기술에서의 입지를 강화했습니다. 이번 인수에는 기증자 참여 앱과 혈액 및 플라스마 수집 산업을 위해 설계된 전문 CRM 플랫폼과 같은 핵심 자산이 포함됩니다.
이 전략적 움직임의 일환으로 Michael Ngo가 Gamma의 전 관리 회원으로서 Paysign의 최고 혁신 책임자로 임명되었습니다. 회사는 또한 비즈니스 전략, AI 기반 분석 및 소프트웨어 개발에 대한 전문성을 갖춘 Howard Steidle, Bei Xu, Sam Wang 등 주요 팀원들을 환영합니다.
이번 통합은 Paysign의 핵심 시장 전반에 걸쳐 참여, 보상 및 자원 관리 솔루션을 향상시키고, 특히 플라스마 고객과의 관계를 강화하며 환자의 경제적 부담을 줄이는 솔루션을 강화하는 것을 목표로 합니다.
Paysign (NASDAQ: PAYS) a acquis les actifs de Gamma Innovation, renforçant ainsi sa position dans les technologies d'engagement des donneurs de plasma et des patients pharmaceutiques. L'acquisition comprend des actifs clés tels qu'une application d'engagement des donneurs et une plateforme CRM spécialisée conçue pour l'industrie de la collecte de sang et de plasma.
Dans le cadre de ce mouvement stratégique, Michael Ngo, ancien membre directeur de Gamma, a été nommé directeur de l'innovation de Paysign. L'entreprise accueille également des membres clés de l'équipe, dont Howard Steidle, Bei Xu et Sam Wang, apportant une expertise en stratégie commerciale, en analyse alimentée par l'IA et en développement de logiciels.
L'intégration vise à améliorer les solutions d'engagement, de compensation et de gestion des ressources de Paysign sur les marchés clés, en renforçant particulièrement les relations avec les clients de plasma et en soutenant les solutions d'accessibilité pour les patients.
Paysign (NASDAQ: PAYS) hat die Vermögenswerte von Gamma Innovation erworben und damit seine Position im Bereich der Technologien für das Engagement von Plasmaspendern und pharmazeutischen Patienten gestärkt. Die Übernahme umfasst wichtige Vermögenswerte wie eine App zur Spenderbindung und eine spezialisierte CRM-Plattform, die für die Blut- und Plasmasammelindustrie entwickelt wurde.
Im Rahmen dieses strategischen Schrittes wurde Michael Ngo, ehemaliges Mitglied der Geschäftsleitung von Gamma, zum Chief Innovation Officer von Paysign ernannt. Das Unternehmen begrüßt auch wichtige Teammitglieder wie Howard Steidle, Bei Xu und Sam Wang, die Expertise in Geschäftsstrategie, KI-gestützter Analyse und Softwareentwicklung mitbringen.
Die Integration zielt darauf ab, die Engagement-, Entschädigungs- und Ressourcenmanagementlösungen von Paysign in den Kernmärkten zu verbessern, insbesondere die Beziehungen zu Plasmakunden zu stärken und Lösungen zur Bezahlbarkeit für Patienten zu fördern.
- Acquisition enhances technological capabilities in plasma donor and pharmaceutical patient engagement
- Gains valuable assets including donor engagement app and specialized CRM platform
- Acquires experienced team with expertise in AI, software development, and business strategy
- Integration expected to reduce operational costs and improve donor retention
- Potential integration risks and challenges mentioned in forward-looking statements
- Possible impact on financial condition due to economic downturn risks
- Regulatory compliance risks in highly regulated environment
Insights
Paysign's acquisition of Gamma Innovation's assets represents a strategic expansion of its technological capabilities in its core markets. The transaction strengthens Paysign's position in the plasma collection industry while enhancing its patient affordability solutions with new donor engagement and management technologies.
This acquisition carries multiple strategic benefits:
- Enhanced donor engagement technologies that could reduce client labor costs and improve donor retention
- A specialized CRM platform tailored specifically for the plasma industry
- Advanced donor management solutions designed to optimize operational efficiency
- An existing customer contract, suggesting immediate revenue potential
Beyond technology assets, Paysign gains valuable human capital through Michael Ngo's appointment as Chief Innovation Officer and the addition of his experienced team. Ngo brings 25 years of industry experience and has developed over 30 mobile and web applications. The team includes expertise in business strategy, AI-driven analytics, and accelerated software delivery.
This move appears well-aligned with Paysign's long-term strategic vision of integrating donor engagement with payment solutions. By acquiring complementary technology rather than competing solutions, Paysign is pursuing vertical integration that could enhance client relationships and potentially create new revenue streams from expanded service offerings.
Paysign Strengthens Leadership in Technology for Plasma and Pharmaceutical Industries
“This acquisition represents an exciting milestone for Paysign as we accelerate our growth strategy and expand our technology-driven solutions,” said Mark Newcomer, President & CEO of Paysign. “Michael and his team have developed innovative donor engagement and management solutions for the blood and plasma collection industry. By integrating Gamma’s technologies, Paysign will deliver enhanced engagement, compensation and resource management solutions across our core markets. These new capabilities will not only strengthen our relationship with plasma clients but will also bolster our patient affordability solutions by incorporating advanced patient retention and adherence tools into that market. We enthusiastically welcome Michael and his team, recognizing their substantial contributions as highly synergistic to Paysign’s long-term strategic vision.”
Michael Ngo, Paysign’s newly appointed Chief Innovation Officer, commented, “We have long admired Paysign’s position as a trusted payments leader in the plasma industry, and it quickly became clear that our shared vision for integrating donor engagement, management and compensation was perfectly aligned. We are eager to deploy our technology to enhance Paysign’s robust solutions for the blood and plasma collection industry and to expand the potential of Paysign’s rapidly growing patient affordability business.”
Among the key assets acquired by Paysign are:
- A donor engagement app, designed to reduce labor costs and donor fees while improving donor retention. The app integrates seamlessly with existing donor management systems, delivering immediate value to plasma centers without complex implementations.
- A specialized customer resource management (CRM) platform tailored specifically for the blood and plasma collection industry, replacing traditional one-size-fits-all CRMs, reducing unnecessary expenses, and improving donor engagement, marketing effectiveness and retention through customizable journey automation tailored to business-defined audiences.
- Additional innovative donor management solutions targeted to the blood and plasma collection industry’s donor engagement/management ecosystem designed to reduce operating costs, optimize donor compensation through intelligent payments and enhance efficiency throughout the donation process.
- An existing contract with a Paysign customer for developing applications that support marketing and donor engagement initiatives.
Michael Ngo is a seasoned technologist and entrepreneur with over 25 years of experience in delivering innovative technology solutions in industries such as finance, pharmaceuticals, enterprise software and digital media. He has led digital transformations, scaled technology ventures and implemented technology initiatives that generated multimillion-dollar growth throughout his career.
Michael has developed over 30 mobile and web applications and consulted for Global Fortune 1000 companies throughout his career. His expertise spans software development, SaaS, digital media and strategic consulting. Previously, he held executive roles at IBM and Citibank’s Software and Technology Services group, focusing on business development, operational efficiency and software implementations.
Paysign also welcomes Michael’s experienced and talented team members, including:
Howard Steidle is a seasoned global business strategist and entrepreneur with an MBA from The Wharton School of the University of
Bei Xu is a recognized leader in AI-driven data analytics with over 25 years of experience in data analytics, artificial intelligence (AI) and digital transformation. She is a results-driven leader in leveraging AI-driven solutions to revolutionize industries, particularly in Life Sciences and Automotive. Ms. Xu has led large-scale AI and data initiatives for Fortune 500 corporations enabling digital transformation, regulatory compliance and operational efficiency. Her expertise in pharmaceutical operations, supply chain management and regulatory reporting has helped Global Fortune 1000 companies harness AI, cloud computing and big data for strategic growth.
Sam Wang is a driving force behind intelligent platform development and accelerated software delivery and is a seasoned software leader with over a decade of experience optimizing the software development life cycle (SDLC) through strategic automation and AI integration. His recent innovations have cut “go-to-market” timelines by 20–
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking under federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. All statements, besides statements of fact included in this release are forward-looking. Such forward-looking statements include, among others, our expectation that we will deliver enhanced engagement, compensation, and resource management solutions across our core markets; our expectation that we will strengthen our relationship with plasma clients and bolster our patient affordability solutions; and our plan to enhance our solutions for the blood and plasma collection industry and to expand our patient affordability business. We caution that these statements are qualified by important risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the inability to continue our current growth rate in future periods; that a downturn in the economy, including as a result of COVID-19 and variants, as well as further government stimulus measures, could reduce our customer base and demand for our products and services, which could have an adverse effect on our business, financial condition, profitability and cash flows; operating in a highly regulated environment; failure by us or business partners to comply with applicable laws and regulations; changes in the laws, regulations, credit card association rules or other industry standards affecting our business; that a data security breach could expose us to liability and protracted and costly litigation; and other risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023. Except to the extent required by federal securities laws, the company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
About Paysign
Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. Incorporated in 1995 and headquartered in southern
About Gamma Innovation LLC
Gamma Innovation LLC is a cutting-edge software and services company focusing on the blood and plasma collection industry that developed innovative solutions targeting donor engagement, retention and management.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325153674/en/
Investor Relations
ir@paysign.com
888.522.4853
paysign.com/investors
Media Relations
Alicia Ches
888.522.4850
pr@paysign.com
Source: Paysign, Inc.
FAQ
What assets did Paysign (PAYS) acquire from Gamma Innovation?
How will the Gamma Innovation acquisition impact Paysign's (PAYS) plasma business?
Who are the key team members joining Paysign (PAYS) through the Gamma acquisition?
What are the main features of the donor engagement app acquired by Paysign (PAYS)?
